Abstract:1,4-dihydropyrimidine-2-thiones were synthesized in five series that include 5-carboxylic acid derivatives of dihydropyrimidine (series A, 6 – 8 ), novel 5-carboxamide derivatives of dihydropyrimidine (series B, 9 – 14 ), N,S - dimethyl - dihydropyrimidine (series C, 15 – 20) , N -hydrazinyl derivatives of dihydropyrimidine (series D, 21 – 24) and tetrazolo dihydropyrimidine derivatives (series E, 25 – 28 ), and evaluated for anti-diabetic capability. The prepared novel compounds were structurally established by FTIR, 1 HNMR, 13 CNMR, ESI and HRMS. All of these compounds from series A - E were first time examined for α-glucosidase inhibition as to evaluate their anti-diabetic potential. Most of the compounds for example 8, 11 – 14, 15, 17 – 21, 25 and 28 demonstrated greater α-glucosidase inhibitory effects (IC 50 = 12.5 ± 0.21 to 47.3 ± 0.23 μM) when compared to deoxynojirimycin as standard (IC 50 = 52.02 ± 0.36 μM). Compounds from series B and C found to be highly active however, the compounds from series D found generally less active. The structure–activity relationships demonstrated the importance of C-5 carboxamides, C-5 ethyl ester functionality, and the presence of N,S-dimethyl groups at pyrimidine ring for α-glucosidase inhibition. The docking studies demonstrated that all the active compounds have van der Waal and alkyl bonds interactions with the targeted site of the human lysosomal acid α −glucosidase. All these compounds were also tested for antioxidant potential by DPPH radical scavenging protocol that exhibited significant antioxidant effects (IC 50 = 21.4 ± 0.45 to 92.1 ± 0.38 μM) as compared to the standard butylated hydroxyanisol (IC 50 = 44.2 ± 0.36 μM). Among all, compound 13, 14 and 19 with potent α-glucosidase inhibition (IC 50 = 18.9 ± 0.72, 23.3 ± 0.45 and 21.5 ± 0.16 μM, respectively) along with excellent antioxidant potential in the range of (IC 50 = 21.4 ± 0.45 to 31.2 ± 0.23 μM) indicated their ability to use as valuable leads for the development of anti-diabetic drugs with the combined effects of antioxidants.

Chemistry and hypoglycemic activity of N-[[(Dialkylamino)alkoxy]phenyl]benzamidines

Chemistry and hypoglycemic activity of benzimidoylpyrazoles

Synthesis and Biological Evaluation of Novel Benzyl-Substituted (S)-Phenylalanine Derivatives As Potent Dipeptidyl Peptidase 4 Inhibitors.

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

[Design, synthesis and hypoglycemic activity of alpha-benzylsuccinic acid derivatives]

Synthesis and characterization of some novel substituted benzenesulphonamides of potential hypoglycemic activity

Synthesis and biological evaluation of sulfonylurea and thiourea derivatives substituted with benzenesulfonamide groups as potential hypoglycemic agents

Synthesis, Characterization, In Silico DFT, Molecular Docking, and Dynamics Simulation Studies of Phenylhydrazono Phenoxyquinolones for Their Hypoglycemic Efficacy

Integrative bioinformatic and experimental analysis of benzoylbenzodioxol derivatives: hypoglycemic potential in diabetic mice

Design, synthesis, molecular dynamic simulation, DFT analysis, computational pharmacology and decoding the antidiabetic molecular mechanism of sulphonamide-thiazolidin-4-one hybrids

Synthesis and Evaluation of Hypoglycemic Activity of Structural Isomers of ((Benzyloxy)phenyl)propanoic Acid Bearing an Aminobornyl Moiety

Insulin-releasing activity of a series of phenylalanine derivatives.

Exploring the anti-diabetic activity of benzimidazole containing Schiff base derivatives: In vitro α-amylase, α-glucosidase inhibitions and in silico studies

Discovery of new 2-phenyl-1H-benzo[d]imidazole core-based potent α-glucosidase inhibitors: Synthesis, kinetic study, molecular docking, and in vivo anti-hyperglycemic evaluation

Novel hybrids of benzothiazole-1,3,4-oxadiazole-4-thiazolidinone: Synthesis, in silico ADME study, molecular docking and in vivo anti-diabetic assessment

Synthesis, highly potent α-glucosidase inhibition, antioxidant and molecular docking of various novel dihydropyrimidine derivatives to treat diabetes mellitus

Design, Synthesis and Biological Evaluation of Novel (E)-2-benzylidene-n-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)hydrazine-1-carboxamide Derivatives As Α-Glucosidase Inhibitors.

A Combined Experimental and Computational Study of Novel Benzotriazinone Carboxamides as Alpha-Glucosidase Inhibitors

Design, synthesis, biological evaluation, and docking study of chromone-based phenylhydrazone and benzoylhydrazone derivatives as antidiabetic agents targeting α‐glucosidase

Novel Benzimidazole-Endowed Chalcones as α-Glucosidase and α-Amylase Inhibitors: An Insight into Structural and Computational Studies

Novel tetrahydrobenzo[b]thiophen-2-yl)urea derivatives as novel α-glucosidase inhibitors: Synthesis, kinetics study, molecular docking, and in vivo anti-hyperglycemic evaluation